PRS 050

Drug Profile

PRS 050

Alternative Names: Angiocal; PRS-050; PRS-050-PEG40

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Pieris
  • Class Antineoplastics
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 01 Jan 2015 Discontinued - Phase-I for Solid tumours (Recurrent, Refractory metastatic disease) in Germany (IV)
  • 04 Dec 2012 PRS-050 is still in phase I trials for Solid tumours in Germany
  • 13 Nov 2011 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011) (3064172; 9131166)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top